Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials

Eitemau Tebyg

• Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials
  gan: Yunfang Yu, et al.
  Cyhoeddwyd: (2020-06-01)
• Joint association of patients’ sex and PD‐L1 expression with overall survival benefits and tumor‐immune microenvironment in immune checkpoint inhibitors for cancers
  gan: Anlin Li, et al.
  Cyhoeddwyd: (2020-06-01)
• Proteinaceous Regulators and Inhibitors of Protein Tyrosine Phosphatases
  gan: Wiljan Hendriks, et al.
  Cyhoeddwyd: (2018-02-01)
• Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
  gan: Mohamed A. Ismail, et al.
  Cyhoeddwyd: (2021-04-01)
• Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1
  gan: Piao, Xianhua, et al.
  Cyhoeddwyd: (1996)